¡Ya estamos en ! Descubre más
icono de AMED

Amedisys
AMED

Excluida de cotización

AMED dejó de cotizar en bolsa el 14 de agosto de 2025.

Volver al ranking
 

Acerca de: Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, and high acuity care segment. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States; the Hospice segment operates many centers designed to provide comfort and support for terminally ill patients; and the High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.

Empleados: 19,000

Atención médica Centros de atención médica

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 0%
Neutral 0%
Negativo 0%
Neutral
PRNewsWire
el año pasado
Twilio Set to Join S&P MidCap 400
NEW YORK , Aug. 14, 2025 /PRNewswire/ -- Twilio Inc. (NYSE: TWLO) will replace Amedisys Inc. (NASD: AMED) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, August 19. S&P 500 and S&P 100 constituent UnitedHealth Group Inc. (NYSE: UNH) acquired Amedisys in a deal completed today.
Twilio Set to Join S&P MidCap 400
Neutral
Reuters
el año pasado
UnitedHealth to sell off 164 locations to settle US challenge to Amedisys deal
UnitedHealth Group has agreed to sell off 164 hospice and home health locations to resolve U.S. antitrust concerns over its $3.3 billion acquisition of Amedisys , the U.S. Justice Department said on Thursday.
UnitedHealth to sell off 164 locations to settle US challenge to Amedisys deal
Negativo
Seeking Alpha
el año pasado
Amedisys: Thoughts On UnitedHealth Merger, Plus Underlying Factors
AMED's planned merger with UnitedHealth remains on the rocks with regulatory overhang still an issue. The deal is also asymmetrically weighted in UNH's favor, with the latter up for no penalty if it fails. Not so for AMED. Aside from this, there are internal factors dragging on AMED's business performance.
Amedisys: Thoughts On UnitedHealth Merger, Plus Underlying Factors
Positivo
Zacks Investment Research
el año pasado
Amedisys (AMED) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amedisys (AMED) is a Top-Ranked Value Stock: Should You Buy?
Positivo
The Motley Fool
el año pasado
Amedisys (AMED) Q2 Revenue Tops 5%
Amedisys (AMED) Q2 Revenue Tops 5%
Amedisys (AMED) Q2 Revenue Tops 5%
Positivo
Zacks Investment Research
el año pasado
Here's What Key Metrics Tell Us About Amedisys (AMED) Q2 Earnings
Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Here's What Key Metrics Tell Us About Amedisys (AMED) Q2 Earnings
Positivo
Zacks Investment Research
el año pasado
Amedisys (AMED) Beats Q2 Earnings and Revenue Estimates
Amedisys (AMED) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.39 per share. This compares to earnings of $1.32 per share a year ago.
Amedisys (AMED) Beats Q2 Earnings and Revenue Estimates
Neutral
GlobeNewsWire
el año pasado
Amedisys Reports Second Quarter 2025 Financial Results
BATON ROUGE, La., July 29, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2025.
Amedisys Reports Second Quarter 2025 Financial Results
Positivo
Zacks Investment Research
el año pasado
Here's Why You Should Retain AMED Stock in Your Portfolio for Now
Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry.
Here's Why You Should Retain AMED Stock in Your Portfolio for Now
Neutral
Zacks Investment Research
el año pasado
AMED or CHE: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and Chemed (CHE). But which of these two stocks offers value investors a better bang for their buck right now?
AMED or CHE: Which Is the Better Value Stock Right Now?
Ver rankings de noticias
Gráficos de precios implementados con Lightweight Charts™